ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2009
Nanotechnology for delivery of drugs to the brain for epilepsy.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 142 citations in OpenAlex.
- Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research.Current clinical pharmacology · 2020Trial
- Recent Development of Nanoparticle Platforms for Organophosphate Nerve Agent Detoxification.Langmuir : the ACS journal of surfaces and colloids · 2025Review
- Unlocking Dendrimers Future Potential for Brain-Specific Drug Delivery in Cerebroanoreach.Recent advances in drug delivery and formulation · 2025Review
- A Comprehensive Overview of the Current Status and Advancements in Various Treatment Strategies against Epilepsy.ACS pharmacology & translational science · 2024Review
- A mix & act liposomes of phospholipase A2-phosphatidylserine for acute brain detoxification by blood‒brain barrier selective-opening.Acta pharmaceutica Sinica. B · 2024Article
- Comparison of neuroprotective effects of a topiramate-loaded biocomposite based on mesoporous silica nanoparticles with pure topiramate against methylphenidate-induced neurodegeneration.Molecular biology reports · 2024Article
- Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A NovelApproach to Diagnosis and Treatment.Pharmaceutical nanotechnology · 2024Review
- Ethosuximide-loaded bismuth ferrite nanoparticles as a potential drug delivery system for the treatment of epilepsy disease.PloS one · 2024Article
- Brain Targeting Nanomedicines: Pitfalls and Promise.International journal of nanomedicine · 2024Review
- Recent Advances in Micro- and Nano-Drug Delivery Systems Based on Natural and Synthetic Biomaterials.Polymers · 2023Review
- Nano-delivery systems as a promising therapeutic potential for epilepsy: Current status and future perspectives.CNS neuroscience & therapeutics · 2023Review
- Ultrasound trapping and navigation of microrobots in the mouse brain vasculature.Nature communications · 2023Article
- Nucleic acid drug vectors for diagnosis and treatment of brain diseases.Signal transduction and targeted therapy · 2023Review
- Translational Considerations in the Development of Intranasal Treatments for Epilepsy.Pharmaceutics · 2023Review
- Synthesis and evaluation of the effects of solid lipid nanoparticles of ivermectin and ivermectin on cuprizone-induced demyelination via targeting the TRPA1/NF-kB/GFAP signaling pathway.Iranian journal of basic medical sciences · 2023Article
- The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug-resistant epilepsy.Epilepsia open · 2022Review
- An On-Demand Drug Delivery System for Control of Epileptiform Seizures.Pharmaceutics · 2022Article
- Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB.Pharmaceutics · 2021Review
- Development of a New Polymeric Nanocarrier Dedicated to Controlled Clozapine Delivery at the Dopamine DPolymers · 2021Review
- Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs.European journal of medicinal chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Epilepsy results from aberrant electrical activity that can affect either a focal area or the entire brain. In treating epilepsy with drugs, the aim is to decrease seizure frequency and severity while minimizing toxicity to the brain and other tissues. Antiepileptic drugs (AEDs) are usually administered by oral and intravenous routes, but these drug treatments are not always effective. Drug access to the brain is severely limited by a number of biological factors, particularly the blood-brain barrier, which impedes the ability of AEDs to enter and remain in the brain. To improve the efficacy of AEDs, new drug delivery strategies are being developed; these methods fall into the three main categories: drug modification, blood-brain barrier modification, and direct drug delivery. Recently, all three methods have been improved through the use of drug-loaded nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.